Translating Preclinical Safety Signals to the Clinic to Inform Compound Discovery and Early Development
- At: 2017 FIP Congress in Stockholm (Sweden)
- Type: Presentation
- By: METTETAL, Jay (AstraZeneca, Drug Safety and Metabolism, Waltham, United States)
- Co-author(s): Jay Mettetal: Drug Safety and Metabolism, AstraZeneca, Waltham, United States
Safety related findings remains a significant driver of compound attrition, particularly during late preclinical and early clinical development. A clearer picture of how early preclinical safety signals translate into man would allow a more accurate assessment potentially lowering attrition and resulting in safer drugs.
Two common questions in.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.